Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
MONTREAL, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Ropack Inc., provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries, announced the purchase of two pharmaceutical facilities in Long Island, New York. The acquisition significantly expands the company’s capabilities which will now include research and development, formulation, lab analysis and commercial and clinical manufacturing, complementing its well-established solid oral dosage packaging and clinical study distribution.
The buildings, formerly operated by Forest Laboratories, LLC, total 213,700 square feet and are a realization of Ropack Inc.’s strategic expansion plan. “It has been a longstanding goal to broaden our service offerings,” noted Yves Massicotte, President and CEO. “To establish a presence in the United States at the same time makes this acquisition ideal.” Activities in the US territory will be managed through Ropack USA Inc. Mr. Massicotte added that Ropack Inc. and Ropack USA Inc. will now be known as “Ropack Pharma Solutions.”
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” remarked Paul Dupont, Vice President of Marketing and Business Development. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
Ropack Inc., celebrating its 40th anniversary in 2016, operates four facilities in Montreal, Canada, for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets. It also is a leading Canadian clinical trial depot. It counts among its current customers many of the largest and most-respected companies in the pharmaceutical and nutraceutical industries.
Contact: Paul Dupont, VP Marketing and Business Development Ropack Pharma Solutions (514) 353-7000 [email protected] [email protected]
